| ŠTEFANČÍKOVÁ, Lenka, Mojmír MOULIS, Pavel FABIAN, Ingrid VÁŠOVÁ, František ZEDEK, Barbora RAVČUKOVÁ, Jan MUŽÍK, Petr KUGLÍK, Vladimíra VRANOVÁ, Iva FALKOVÁ, Renata HRABÁLKOVÁ a Jana ŠMARDOVÁ. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Online. International Journal of Oncology. 2011, roč. 39, č. 6, s. 1413-1420. ISSN 1019-6439. Dostupné z: https://dx.doi.org/10.3892/ijo.2011.1170. [citováno 2024-04-24] |
Další formáty:
BibTeX
LaTeX
RIS
@article{970414,
author = {Štefančíková, Lenka and Moulis, Mojmír and Fabian, Pavel and Vášová, Ingrid and Zedek, František and Ravčuková, Barbora and Mužík, Jan and Kuglík, Petr and Vranová, Vladimíra and Falková, Iva and Hrabálková, Renata and Šmardová, Jana},
article_number = {6},
doi = {http://dx.doi.org/10.3892/ijo.2011.1170},
keywords = {diffuse large B-cell lymphoma; tumor suppressor p53; FASAY; overall survival; progression free survival},
language = {eng},
issn = {1019-6439},
journal = {International Journal of Oncology},
title = {Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma},
volume = {39},
year = {2011}
}
TY - JOUR
ID - 970414
AU - Štefančíková, Lenka - Moulis, Mojmír - Fabian, Pavel - Vášová, Ingrid - Zedek, František - Ravčuková, Barbora - Mužík, Jan - Kuglík, Petr - Vranová, Vladimíra - Falková, Iva - Hrabálková, Renata - Šmardová, Jana
PY - 2011
TI - Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma
JF - International Journal of Oncology
VL - 39
IS - 6
SP - 1413-1420
EP - 1413-1420
SN - 10196439
KW - diffuse large B-cell lymphoma
KW - tumor suppressor p53
KW - FASAY
KW - overall survival
KW - progression free survival
N2 - We performed complex analysis of the p53 tumor suppressor in collection of 75 DLBCL cases. Fifty four patients were de novo cases, twenty one cases developed into DLBCL by transformation from less aggressive disease. We determined functional status by analysis of separated alleles in yeast (FASAY) and analyzed the p53 mutations by cDNA sequencing. We assessed the level of the p53 protein by immunoblotting analysis. We used FISH to analyze loss of the p53 and ATM (ataxia telangiectasia mutated) genes deletion. We detected 16 p53 mutations (21.3%) including the mutation activating nonsense-mediated RNA decay pathway. Deletion of the p53 allele was more common in cases with p53 mutation. Mutations and/or deletions of p53 had statistically significant negative impact on progression-free survival and tended to decrease also overall survival in 46 de novo DLBCL patients treated with R-CHOP. p53 aberrations are negative predictors for survival of DLBCL patients treated with R-CHOP.
ER -
ŠTEFANČÍKOVÁ, Lenka, Mojmír MOULIS, Pavel FABIAN, Ingrid VÁŠOVÁ, František ZEDEK, Barbora RAVČUKOVÁ, Jan MUŽÍK, Petr KUGLÍK, Vladimíra VRANOVÁ, Iva FALKOVÁ, Renata HRABÁLKOVÁ a Jana ŠMARDOVÁ. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Online. \textit{International Journal of Oncology}. 2011, roč.~39, č.~6, s.~1413-1420. ISSN~1019-6439. Dostupné z: https://dx.doi.org/10.3892/ijo.2011.1170. [citováno 2024-04-24]
|
